All the data crunching is done. There’s nothing left to do but have meetings and file.
Any further analysis of the Alz data will bear little fruit and is probably a waste of time and money.
I’m still hoping for that partnership announcement. Otherwise it seems 2-73 may be stalled for a while. A lot of time and money dedicated to filing, analysis of a Rett data, and 3-71 trial.
They can’t be spread much thinner. We have all the data that is needed to design and move forward with multiple 2-73 trials. With confidence. We’ve learned from our mistakes hopefully and will likely emerge stronger but desperately need that muscle.
Years go by quick, patent expirations go by quick and competitors move quickly. Now is the right time for expertise, money and infrastructure. For Alz and all other trials.
Missling is no dummy. He has his pulse on the cns world and is aware of who and what’s moving forward. Try to salvage Rett without letting the voucher cloud his judgement and move on full speed.
News 
Market Data 
Discover 
